FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382776315> ?p ?o ?g. }

• W4382776315 abstract "Triple-negative breast cancer (TNBC) is the most heterogenous and aggressive subtype of breast cancer. Chemotherapy remains the standard treatment option for patients with TNBC owing to the unavailability of acceptable targets and biomarkers in clinical practice. Novel biomarkers and targets for patient stratification and treatment of TNBC are urgently needed. It has been reported that the overexpression of DNA damage-inducible transcript 4 gene (DDIT4) is associated with resistance to neoadjuvant chemotherapy and poor prognosis in patients with TNBC. In this study, we aimed to identify novel biomarkers and therapeutic targets using RNA sequencing (RNA-seq) and data mining using data from public databases.RNA sequencing (RNA-Seq) was performed to detect the different gene expression patterns in the human TNBC cell line HS578T treated with docetaxel or doxorubicin. Sequencing data were further analyzed by the R package edgeR and clusterProfiler to identify the profile of differentially expressed genes (DEGs) and annotate gene functions. The prognostic and predictive value of DDIT4 expression in patients with TNBC was further validated by published online data resources, including TIMER, UALCAN, Kaplan-Meier plotter, and LinkedOmics, and GeneMANIA and GSCALite were used to investigate the functional networks and hub genes related to DDIT4, respectively.Through the integrative analyses of RNA-Seq data and public datasets, we observed the overexpression of DDIT4 in TNBC tissues and found that patients with DDIT4 overexpression showed poor survival outcomes. Notably, immune infiltration analysis showed that the levels of DDIT4 expression correlated negatively with the abundance of tumor-infiltrating immune cells and immune biomarker expression, but correlated positively with immune checkpoint molecules. Furthermore, DDIT4 and its hub genes (ADM, ENO1, PLOD1, and CEBPB) involved in the activation of apoptosis, cell cycle, and EMT pathways. Eventually, we found ADM, ENO1, PLOD1, and CEBPB showed poor overall survival in BC patients.In this study, we found that DDIT4 expression is associated with the progression, therapeutic efficacy, and immune microenvironment of patients with TNBC, and DDIT4 would be as a potential prognostic biomarker and therapeutic target. These findings will help to identify potential molecular targets and improve therapeutic strategies against TNBC." @default.
• W4382776315 created "2023-07-02" @default.
• W4382776315 creator A5003047526 @default.
• W4382776315 creator A5020637697 @default.
• W4382776315 creator A5024837226 @default.
• W4382776315 creator A5025310044 @default.
• W4382776315 creator A5038179020 @default.
• W4382776315 creator A5039080845 @default.
• W4382776315 creator A5063070943 @default.
• W4382776315 creator A5090622915 @default.
• W4382776315 date "2023-06-30" @default.
• W4382776315 modified "2023-09-25" @default.
• W4382776315 title "Identification of DDIT4 as a potential prognostic marker associated with chemotherapeutic and immunotherapeutic response in triple-negative breast cancer" @default.
• W4382776315 cites W1978510296 @default.
• W4382776315 cites W1987395624 @default.
• W4382776315 cites W2035618305 @default.
• W4382776315 cites W2050457398 @default.
• W4382776315 cites W2101208037 @default.
• W4382776315 cites W2134539328 @default.
• W4382776315 cites W2135410441 @default.
• W4382776315 cites W2253691911 @default.
• W4382776315 cites W2402915236 @default.
• W4382776315 cites W2430731787 @default.
• W4382776315 cites W2593111137 @default.
• W4382776315 cites W2594467284 @default.
• W4382776315 cites W2611636955 @default.
• W4382776315 cites W2736730167 @default.
• W4382776315 cites W2765224588 @default.
• W4382776315 cites W2766212588 @default.
• W4382776315 cites W2766673799 @default.
• W4382776315 cites W2767377392 @default.
• W4382776315 cites W2785041354 @default.
• W4382776315 cites W2794018125 @default.
• W4382776315 cites W2801279436 @default.
• W4382776315 cites W2803157002 @default.
• W4382776315 cites W2803985368 @default.
• W4382776315 cites W2804658429 @default.
• W4382776315 cites W2806830990 @default.
• W4382776315 cites W2809000676 @default.
• W4382776315 cites W2810896552 @default.
• W4382776315 cites W2825767749 @default.
• W4382776315 cites W2893677817 @default.
• W4382776315 cites W2901662666 @default.
• W4382776315 cites W2913526841 @default.
• W4382776315 cites W2918412223 @default.
• W4382776315 cites W2919814435 @default.
• W4382776315 cites W2921768356 @default.
• W4382776315 cites W2930471260 @default.
• W4382776315 cites W2930553605 @default.
• W4382776315 cites W2955485789 @default.
• W4382776315 cites W2986359625 @default.
• W4382776315 cites W2993746674 @default.
• W4382776315 cites W3006201797 @default.
• W4382776315 cites W3020766569 @default.
• W4382776315 cites W3024764930 @default.
• W4382776315 cites W3037083586 @default.
• W4382776315 cites W3044428842 @default.
• W4382776315 cites W3048450071 @default.
• W4382776315 cites W3101436145 @default.
• W4382776315 cites W3136703878 @default.
• W4382776315 cites W3171164709 @default.
• W4382776315 cites W3175173749 @default.
• W4382776315 cites W3196421823 @default.
• W4382776315 cites W3196783230 @default.
• W4382776315 cites W3202490153 @default.
• W4382776315 cites W4212767395 @default.
• W4382776315 cites W4283156085 @default.
• W4382776315 cites W4285992810 @default.
• W4382776315 cites W2896044683 @default.
• W4382776315 doi "https://doi.org/10.1186/s12957-023-03078-7" @default.
• W4382776315 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37391802" @default.
• W4382776315 hasPublicationYear "2023" @default.
• W4382776315 type Work @default.
• W4382776315 citedByCount "0" @default.
• W4382776315 crossrefType "journal-article" @default.
• W4382776315 hasAuthorship W4382776315A5003047526 @default.
• W4382776315 hasAuthorship W4382776315A5020637697 @default.
• W4382776315 hasAuthorship W4382776315A5024837226 @default.
• W4382776315 hasAuthorship W4382776315A5025310044 @default.
• W4382776315 hasAuthorship W4382776315A5038179020 @default.
• W4382776315 hasAuthorship W4382776315A5039080845 @default.
• W4382776315 hasAuthorship W4382776315A5063070943 @default.
• W4382776315 hasAuthorship W4382776315A5090622915 @default.
• W4382776315 hasBestOaLocation W43827763151 @default.
• W4382776315 hasConcept C121608353 @default.
• W4382776315 hasConcept C126322002 @default.
• W4382776315 hasConcept C143998085 @default.
• W4382776315 hasConcept C203014093 @default.
• W4382776315 hasConcept C2780110267 @default.
• W4382776315 hasConcept C2780140570 @default.
• W4382776315 hasConcept C2781197716 @default.
• W4382776315 hasConcept C502942594 @default.
• W4382776315 hasConcept C530470458 @default.
• W4382776315 hasConcept C54355233 @default.
• W4382776315 hasConcept C60644358 @default.
• W4382776315 hasConcept C71924100 @default.
• W4382776315 hasConcept C86803240 @default.
• W4382776315 hasConcept C8891405 @default.
• W4382776315 hasConceptScore W4382776315C121608353 @default.
• W4382776315 hasConceptScore W4382776315C126322002 @default.

• next